QNOpen Access

Recent advancements in quantum dot (QD)-based electrochemical sensors have shown significant promise for the early detection and monitoring of blood cancers, such as leukemia and lymphoma. QDs, with their unique optical properties, high surface area, and tunable fluorescence, offer highly sensitive and specific detection of cancer biomarkers, enabling rapid, real-time diagnostics. These sensors are capable of multiplexed detection, allowing for the simultaneous identification of multiple biomarkers or circulating tumor cells (CTCs), crucial for early diagnosis and monitoring minimal residual disease (MRD). Despite their potential, challenges remain, including concerns over biocompatibility, toxicity, and the need for regulatory approval. Future research is focused on addressing these issues by developing non-toxic, biocompatible QDs, optimizing sensor performance, and integrating these technologies into point-of-care devices. Additionally, the combination of electrochemical and optical sensing techniques, along with advancements in surface modification and signal enhancement, holds promise for further improving the sensitivity, reliability, and clinical applicability of QD-based sensors. As research progresses, QD-based electrochemical sensors are poised to become a powerful tool for non-invasive, early-stage blood cancer detection and personalized treatment monitoring.